Literature DB >> 3486630

In vitro comparison of ampicillin-chloramphenicol and ampicillin-cefotaxime against 284 Haemophilus isolates.

J R Lapointe, C Lavallée, A Michaud, L Chicoine, J H Joncas.   

Abstract

Since November 1982 at the Sainte-Justine Hospital in Montreal, ampicillin and cefotaxime were used in association as initial treatment (greater than or equal to 48 h) for childhood bacterial meningitis. In this report is described the in vitro interaction of the new regimen in comparison with that of the previous ampicillin-chloramphenicol combination against 284 Haemophilus isolates. Among the 156 ampicillin-susceptible, beta-lactamase-negative isolates, synergy was detected in 13 with ampicillin-cefotaxime, and antagonism was detected in only 1; in contrast, synergy was found in only 2 strains with ampicillin-chloramphenicol, and antagonism was found in 15. These differences were statistically significant (P less than 0.01). Such significant differences were not observed among the 128 ampicillin-resistant, beta-lactamase-positive Haemophilus isolates. The synergy of ampicillin-cefotaxime did not contribute to a decrease of the MIC of cefotaxime for 90% of isolates tested, whereas the antagonism of ampicillin-chloramphenicol did not contribute to increase the MIC of ampicillin for 90% of isolates tested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486630      PMCID: PMC180448          DOI: 10.1128/AAC.29.4.594

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis.

Authors:  W E Feldman
Journal:  J Pediatr       Date:  1976-04       Impact factor: 4.406

2.  Long-term outcome of Hemophilus influenzae meningitis related to antiobiotic treatment.

Authors:  J Lindberg; U Rosenhall; O Nylén; A Ringnér
Journal:  Pediatrics       Date:  1977-07       Impact factor: 7.124

3.  Mechanism of action of penicillin: triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis.

Authors:  A Tomasz; S Waks
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

4.  Antibiotic antagonism in bacterial meningitis.

Authors:  A W Mathies; J M Leedom; D Ivler; P F Wehrle; B Portnoy
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

5.  Effect of ampicillin and chloramphenicol against Haemophilus influenzae.

Authors:  W E Feldman
Journal:  Pediatrics       Date:  1978-03       Impact factor: 7.124

6.  Combined action of chloramphenicol and ampicillin on Haemophilus influenzae.

Authors:  A M Mackenzie
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

7.  Chloramphenicol inhibition of the bactericidal effect of ampicillin against Haemophilus influenzae.

Authors:  V Rocco; G Overturf
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

9.  A comparison of ampicillin-cefotaxime and ampicillin-chloramphenicol in childhood bacterial meningitis: an experience in 55 patients.

Authors:  J R Lapointe; C Béliveau; L Chicoine; J H Joncas
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

10.  Iodometric detection of Haemophilus influenzae beta-lactamase: rapid presumptive test for ampicillin resistance.

Authors:  B W Catlin
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

View more
  2 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Antibiotic therapy of meningitis caused by ampicillin-resistant Haemophilus influenzae in Denmark and Greenland 1981 to 1987.

Authors:  T Cordtz; O B Jepsen; M Arpi; P Hønberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.